Biontech Says European Patent Office's Decision To Maintain Moderna's Patent EP No. 3 590 949 B1 In Amended Form Does Not Change Co's Stance On Patent; Says "Believe That Neither Ep '949 Nor Any Of The Auxiliary Requests Filed By Moderna Meet The Requirements For Patentability"; Says "Will Continue To Vigorously Defend" Its Innovations Against All Allegations Of Patent Infringement Including EP '949 Case
Portfolio Pulse from Benzinga Newsdesk
BioNTech has stated that the European Patent Office's decision to maintain Moderna's patent EP No. 3 590 949 B1 in amended form does not change its stance on the patent. BioNTech believes that neither the patent nor any auxiliary requests filed by Moderna meet the requirements for patentability and will continue to defend its innovations against all allegations of patent infringement, including the EP '949 case.
May 17, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech has reaffirmed its position against Moderna's patent EP No. 3 590 949 B1, stating that it does not meet patentability requirements. The company will continue to defend its innovations against all allegations of patent infringement.
BioNTech's firm stance and commitment to defending its innovations suggest ongoing legal battles, but the immediate impact on stock price is neutral as the decision does not change the company's position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Moderna's patent EP No. 3 590 949 B1 has been maintained in amended form by the European Patent Office. However, BioNTech continues to challenge the patent's validity and will defend its innovations against allegations of infringement.
While the European Patent Office's decision is a positive for Moderna, BioNTech's continued challenge indicates ongoing legal disputes, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100